GLP-1 Analogs Receive Green Light for Clinical Evaluation in Substance Use Treatment
PILLAR DIAGNOSTIC // WEEK 32
“With no conflicting findings across pillars, the data uniformly support a favorable benefit–risk balance for GLP-1 analogs. Preclinical safety (NOAEL 0.062 mg/kg in rabbits), consistent efficacy signals, and no differential retinopathy risk converge to a low overall risk posture.”
Proposed action
Advance to well-controlled clinical evaluations with standard safety monitoring (e.g., GI tolerability, metabolic parameters) and real-world evidence collection to confirm long-term outcomes.
THE MECHANICS
Spread & delivery
—
THE MACHINE
Evidence & systems
GLP-1 analogs such as semaglutide, exenatide, dulaglutide, and liraglutide—originally developed for obesity and type 2 diabetes—show potential in reducing substance use, have a NOAEL of 0.062 mg/kg in rabbits for semaglutide, and present no differential risk of sight-threatening diabetic retinopathy across agents.
THE MAP
Policy & population
—
THE MOOD
Trust & behavior
—